Evoke Pharma, Inc. - EVOK STOCK NEWS

Evoke Pharma (NASDAQ: EVOK) and EVERSANA have confirmed the extension of their collaboration agreement for the commercialization of Gimoti^® (metoclopramide) nasal spray in the U.S. until December 31, 2026. This partnership, originally established in January 2020, enables Evoke to retain ownership of Gimoti while allowing EVERSANA to manage market access, marketing, and distribution. The updated agreement enhances Evoke's profit retention from Gimoti sales and accelerates cost reimbursements. Gimoti addresses significant needs in diabetic gastroparesis treatment.

Evoke Pharma, a specialty pharmaceutical company focused on gastrointestinal treatments, will participate in the H.C. Wainwright BIOCONNECT Conference from January 10-13, 2022. Management's presentation will be accessible online starting January 10 at 7:00 a.m. ET. Investors interested in one-on-one meetings may contact a representative or Daniel Kontoh-Boateng. Evoke is known for GIMOTI, a nasal spray for diabetic gastroparesis relief, currently the only FDA-approved drug for this condition in the U.S., targeting a significant patient population worldwide.

Evoke Pharma, Inc. (NASDAQ: EVOK) reported a net loss of approximately $2.0 million for Q3 2021, slightly improved from $2.1 million in Q3 2020. Net product sales surged to around $930,000, driven by a notable increase in GIMOTI prescriptions. Research and development expenses decreased to $0.1 million, while selling, general, and administrative (SG&A) expenses rose to $2.6 million due to commercialization efforts. As of September 30, 2021, cash reserves stood at about $11.1 million, projected to support operations until Q3 2022. GIMOTI continues to gain traction among healthcare providers.

Evoke Pharma, focused on gastrointestinal treatments, plans to release its third-quarter 2021 financial results on November 10, 2021, post-market. A conference call will follow at 4:30 p.m. ET to discuss these results. The company has commercialized GIMOTI, a nasal spray for diabetic gastroparesis, the only FDA-approved treatment for this condition. Evoke emphasizes the market potential for GIMOTI amid ongoing challenges, including reliance on third-party manufacturing and market demand dynamics. The company warns of various risks that could impact operations and revenue generation.

Evoke Pharma (NASDAQ: EVOK) announced positive results from a recent market study on its GIMOTI® (metoclopramide) nasal spray. Conducted by EVERSANA, the study revealed that 92% of healthcare practitioners intend to prescribe GIMOTI, up from previous surveys. Key findings highlight a shift in preference for nasal administration over oral, with 45% of gastroenterologists favoring this route. The company will present these insights at the ACG Conference in Las Vegas on October 22-27, 2021.

Evoke Pharma and EVERSANA received the Sales Aid Silver Award for their "Spray Away" campaign promoting GIMOTI, a nasal spray for Diabetic Gastroparesis, at the PM360 Trailblazer Initiative Awards held on September 23, 2021. The campaign highlights GIMOTI's innovative delivery method, aiding patients who struggle with oral medications due to nausea or gastric delay. Since launching GIMOTI in October 2020, Evoke has achieved nearly 9 million media impressions and continues to enhance awareness among healthcare providers and patients.

Evoke Pharma, Inc. (NASDAQ: EVOK) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Dave Gonyer and CBO Matt D’Onofrio will engage in a virtual presentation on September 13, which will be available on-demand starting at 7:00 am ET.

This conference will include corporate presentations and one-on-one meetings. Interested investors can schedule calls with Evoke management via their H.C. Wainwright representative.

Evoke Pharma reported a 162% increase in product sales and 152% growth in prescriptions for Gimoti in Q2 2021. The company expanded its base of new prescribers significantly, with a rise from 84 to 132 over the quarter. Net loss decreased to approximately $2.3 million from $7.0 million year-over-year, while net product sales reached $237,000. Total operating expenses were $2.4 million, down from $7.0 million in Q2 2020. As of June 30, 2021, cash equivalents stood at $16.7 million, expected to support operations until Q3 2022.

Evoke Pharma, Inc. (Nasdaq: EVOK), focused on GI treatments, will release its Q2 2021 financial results on August 12, 2021, post-market. A conference call will follow at 4:30 p.m. ET to discuss the results, with dial-in numbers provided for domestic and international participants. The company is known for GIMOTI^®, a nasal spray for diabetic gastroparesis, the only FDA-approved treatment in the U.S. for this condition. Evoke cautions that forward-looking statements may not guarantee future results due to various risks, including reliance on GIMOTI and potential disruptions from COVID-19.